58 research outputs found
Recent Developments in the Inhibition of Bacterial Adhesion as Promising Anti-Virulence Strategy
Infectious diseases caused by antimicrobial-resistant strains have become a serious threat to global health, with a high social and economic impact. Multi-resistant bacteria exhibit various mechanisms at both the cellular and microbial community levels. Among the different strategies proposed to fight antibiotic resistance, we reckon that the inhibition of bacterial adhesion to host surfaces represents one of the most valid approaches, since it hampers bacterial virulence without affecting cell viability. Many different structures and biomolecules involved in the adhesion of Gram-positive and Gram-negative pathogens can be considered valuable targets for the development of promising tools to enrich our arsenal against pathogens
Optimization of coupled advanced oxidation processes and activated carbons for purification of salt water
Photocatalysis, ozonation and activated carbons were investigated separately and in combination as tools for the purification of polluted salt water. Coupling different processes enables to overcome many drawbacks related to the use of the single technologies and at the same time to exploit possible synergistic effects. In this work a kinetic analysis was
performed for modelling the degradation of 4-nitrophenol (4NP) as a probe pollutant molecule in synthetic seawater.
Thus, the optimum synergistic conditions of the three processes acting together were determined and discussed
Magnetic Resonance Imaging Confirmed Olfactory Bulb Reduction in Long COVID-19: Literature Review and Case Series
An altered sense of smell and taste was recognized as one of the most characteristic symptoms of coronavirus infection disease (COVID-19). Despite most patients experiencing a complete functional resolution, there is a 21.3% prevalence of persistent alteration at 12 months after infection. To date, magnetic resonance imaging (MRI) findings in these patients have been variable and not clearly defined. We aimed to clarify radiological alterations of olfactory pathways in patients with long COVID-19 characterized by olfactory dysfunction. A comprehensive review of the English literature was performed by analyzing relevant papers about this topic. A case series was presented: all patients underwent complete otorhinolaryngology evaluation including the Sniffin’ Sticks battery test. A previous diagnosis of SARS-CoV-2 infection was confirmed by positive swabs. The MRIs were acquired using a 3.0T MR scanner with a standardized protocol for olfactory tract analysis. Images were first analysed by a dedicated neuroradiologist and subsequently reviewed and compared with the previous available MRIs. The review of the literature retrieved 25 studies; most cases of olfactory dysfunction more than 3 months after SARS-CoV-2 infection showed olfactory bulb (OB) reduction. Patients in the personal case series had asymmetry and a reduction in the volume of the OB. This evidence was strengthened by the comparison with a previous MRI, where the OBs were normal. The results preliminarily confirmed OB reduction in cases of long COVID-19 with an altered sense of smell. Further studies are needed to clarify the epidemiology, pathophysiology and prognosis
A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal form of cancer characterized
by drug resistance, urging new therapeutic strategies. In recent years, protein kinases have emerged
as promising pharmacological targets for the treatment of several solid and hematological tumors.
Interestingly, cyclin-dependent kinase 1 (CDK1) is overexpressed in PDAC tissues and has been
correlated to the aggressive nature of these tumors because of its key role in cell cycle progression
and resistance to the induction of apoptosis. For these reasons, CDK1 is one of the main causes
of chemoresistance, representing a promising pharmacological target. In this study, we report the
synthesis of new 1,2,4-oxadiazole compounds and evaluate their ability to inhibit the cell growth of
PATU-T, Hs766T, and HPAF-II cell lines and a primary PDAC cell culture (PDAC3). Compound 6b
was the most active compound, with IC50 values ranging from 5.7 to 10.7 M. Molecular docking
of 6b into the active site of CDK1 showed the ability of the compound to interact effectively with
the adenosine triphosphate binding pocket. Therefore, we assessed its ability to induce apoptosis
(which increased 1.5- and 2-fold in PATU-T and PDAC3 cells, respectively) and to inhibit CDK1
expression, which was reduced to 45% in Hs766T. Lastly, compound 6b passed the ADME prediction,
showing good pharmacokinetic parameters. These data demonstrate that 6b displays cytotoxic
activity, induces apoptosis, and targets CDK1, supporting further studies for the development of
similar compounds against PDAC
1,3,4-Oxadiazole and 1,3,4-Thiadiazole Nortopsentin Derivatives against Pancreatic Ductal Adenocarcinoma: Synthesis, Cytotoxic Activity, and Inhibition of CDK1
A new series of nortopsentin analogs, in which the central imidazole ring of the natural lead was replaced by a 1,3,4-oxadiazole or 1,3,4-thiadiazole moiety, was efficiently synthesized. The antiproliferative activity of all synthesized derivatives was evaluated against five pancreatic ductal adenocarcinoma (PDAC) cell lines, a primary culture and a gemcitabine-resistant variant. The five more potent compounds elicited EC50 values in the submicromolar-micromolar range, associated with a significant reduction in cell migration. Moreover, flow cytometric analysis after propidium iodide staining revealed an increase in the G2-M and a decrease in G1-phase, indicating cell cycle arrest, while a specific ELISA demonstrated the inhibition of CDK1 activity, a crucial regulator of cell cycle progression and cancer cell proliferation
Discovery of the 3-Amino-1,2,4-triazine-Based Library as Selective PDK1 Inhibitors with Therapeutic Potential in Highly Aggressive Pancreatic Ductal Adenocarcinoma
Pyruvate dehydrogenase kinases (PDKs) are serine/threonine kinases, that are directly involved in altered cancer cell metabolism, resulting in cancer aggressiveness and resistance. Dichloroacetic acid (DCA) is the first PDK inhibitor that has entered phase II clinical; however, several side effects associated with weak anticancer activity and excessive drug dose (100 mg/kg) have led to its limitation in clinical application. Building upon a molecular hybridization approach, a small library of 3-amino-1,2,4-triazine derivatives has been designed, synthesized, and characterized for their PDK inhibitory activity using in silico, in vitro, and in vivo assays. Biochemical screenings showed that all synthesized compounds are potent and subtype-selective inhibitors of PDK. Accordingly, molecular modeling studies revealed that a lot of ligands can be properly placed inside the ATP-binding site of PDK1. Interestingly, 2D and 3D cell studies revealed their ability to induce cancer cell death at low micromolar doses, being extremely effective against human pancreatic KRAS mutated cancer cells. Cellular mechanistic studies confirm their ability to hamper the PDK/PDH axis, thus leading to metabolic/redox cellular impairment, and to ultimately trigger apoptotic cancer cell death. Remarkably, preliminary in vivo studies performed on a highly aggressive and metastatic Kras-mutant solid tumor model confirm the ability of the most representative compound 5i to target the PDH/PDK axis in vivo and highlighted its equal efficacy and better tolerability profile with respect to those elicited by the reference FDA approved drugs, cisplatin and gemcitabine. Collectively, the data highlights the promising anticancer potential of these novel PDK-targeting derivatives toward obtaining clinical candidates for combatting highly aggressive KRAS-mutant pancreatic ductal adenocarcinomas
Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells
A new series of eighteen imidazo [2,1-b] [1,3,4]thiadiazole derivatives was efficiently synthesized and
screened for antiproliferative activity against the National Cancer Institute (NCI-60) cell lines panel. Two
out of eighteen derivatives, compounds 12a and 12h, showed remarkably cytotoxic activity with the half
maximal inhibitory concentration values (IC50) ranging from 0.23 to 11.4 mM, and 0.29e12.2 mM,
respectively. However, two additional compounds, 12b and 13g, displayed remarkable in vitro antiproliferative
activity against pancreatic ductal adenocarcinoma (PDAC) cell lines, including immortalized
(SUIT-2, Capan-1, Panc-1), primary (PDAC-3) and gemcitabine-resistant (Panc-1R), eliciting IC50 values
ranging from micromolar to sub-micromolar level, associated with significant reduction of cell-migration
and spheroid shrinkage. These remarkable results might be explained by modulation of key regulators of
epithelial-to-mesenchymal transition (EMT), including E-cadherin and vimentin, and inhibition of
metalloproteinase-2/-9. High-throughput arrays revealed a significant inhibition of the phosphorylation
of 45 tyrosine kinases substrates, whose visualization on Cytoscape highlighted PTK2/FAK as an
important hub. Inhibition of phosphorylation of PTK2/FAK was validated as one of the possible mechanisms
of action, using a specific ELISA. In conclusion, novel imidazothiadiazoles show potent antiproliferative
activity, mediated by modulation of EMT and PTK2/FAK
Structural Manipulations of Marine Natural Products Inspire a New Library of 3-Amino-1,2,4-Triazine PDK Inhibitors Endowed with Antitumor Activity in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the main aggressive types of cancer, characterized by late prognosis and drug resistance. Among the main factors sustaining PDAC progression, the alteration of cell metabolism has emerged to have a key role in PDAC cell proliferation, invasion, and resistance to standard chemotherapeutic agents. Taking into account all these factors and the urgency in evaluating novel options to treat PDAC, in the present work we reported the synthesis of a new series of indolyl-7-azaindolyl triazine compounds inspired by marine bis-indolyl alkaloids. We first assessed the ability of the new triazine compounds to inhibit the enzymatic activity of pyruvate dehydrogenase kinases (PDKs). The results showed that most of derivatives totally inhibit PDK1 and PDK4. Molecular docking analysis was executed to predict the possible binding mode of these derivatives using ligand-based homology modeling technique. Evaluation of the capability of new triazines to inhibit the cell growth in 2D and 3D KRAS-wild-type (BxPC-3) and KRAS-mutant (PSN-1) PDAC cell line, was carried out. The results showed the capacity of the new derivatives to reduce cell growth with a major selectivity against KRAS-mutant PDAC PSN-1 on both cell models. These data demonstrated that the new triazine derivatives target PDK1 enzymatic activity and exhibit cytotoxic effects on 2D and 3D PDAC cell models, thus encouraging further structure manipulation for analogs development against PDA
CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin
Limited therapeutic options are available for advanced colorectal cancer (CRC). Herein, we report that exposure to a neo-synthetic bis(indolyl)thiazole alkaloid analog, nortopsentin 234 (NORA234), leads to an initial reduction of proliferative and clonogenic potential of CRC sphere cells (CR-CSphCs), followed by an adaptive response selecting the CR-CSphC-resistant compartment. Cells spared by the treatment with NORA234 express high levels of CD44v6, associated with a constitutive activation of Wnt pathway. In CR-CSphC-based organoids, NORA234 causes a genotoxic stress paralleled by G2-M cell cycle arrest and activation of CHK1, driving the DNA damage repair of CR-CSphCs, regardless of the mutational background, microsatellite stability, and consensus molecular subtype. Synergistic combination of NORA234 and CHK1 (rabusertib) targeting is synthetic lethal inducing death of both CD44v6-negative and CD44v6-positive CRC stem cell fractions, aside from Wnt pathway activity. These data could provide a rational basis to develop an effective strategy for the treatment of patients with CRC
Therapeutic strategies to counteract antibiotic resistance in MRSA biofilm-associated infections
Methicillin-resistant Staphylococcus aureus (MRSA) has
emerged as one of the leading cause of persistent human infections.
This pathogen is widespread and is able to colonize
asymptomatically about a third of the population causing moderate
to severe infections. It is currently considered the most common
cause of nosocomial infections and one of the main cause of death
in hospitalized patients. Due to its high morbidity and mortality rate
and its ability to resist to most antibiotics on the market, it was
defined a “superbug”. Its ability to form biofilm on biotic and abiotic
surfaces seems to be the primarily responsible of MRSA antibiotic
resistance and pervasiveness. Importantly, more than 80% of
bacterial infections are biofilm-mediated. Biofilm formation on
indwelling catheters, prosthetic devices and implants is recognized
as cause of serious chronic infections in hospital environment. In this
review we discussed the most relevant literature of the last five years
concerning the development of synthetic small molecules able to
inhibit biofilm formation or to eradicate or disperse pre-formed
biofilms in the fight against MRSA diseases. The aim is to provide
guidelines for the development of new anti-virulence strategies
based on the knowledge so far acquired, and, to identify the main
flaws of this research field, which did not allow to obtain new anti-
MRSA drugs market-approved able to act against biofilm-associated
infection
- …